胰头癌合并门静脉和/或肠系膜上静脉及空肠静脉切除的胰十二指肠切除术手术结局:多中心研究
这项多中心研究纳入2013至2016年间50家机构共1260例接受门静脉和/或肠系膜上静脉(PV/SMV)切除的胰腺切除术患者,比较未合并空肠静脉切除组、合并第一空肠静脉切除组及合并第二或更远端空肠静脉分支切除组的手术结局。三组术后并发症与死亡率无显著差异,合并空肠静脉切除可安全实施,并可能在围手术期辅助治疗下获得满意的总生存。
要点
- PV/SMV切除合并空肠静脉切除的术后并发症与死亡率与未合并空肠静脉切除者无显著差异。
- PV/SMV组与PV/SMV-J1V组总生存无显著差异(中位生存29.2 vs 30.9个月,P=0.60)。
- PV/SMV-J2,3V组在直接手术患者中生存显著短于PV/SMV组(P=0.05),但接受术前治疗者总生存无显著差异。
核心结论
- PV/SMV切除合并空肠静脉切除可安全实施,并可能在术前及术后辅助治疗下提供满意的总生存。
研究设计与样本
- 多中心研究,纳入2013至2016年间50家机构共1260例接受胰腺切除术合并PV/SMV切除的患者。
- 按空肠静脉切除情况分为PV/SMV组(未合并空肠静脉切除,n=824)、PV/SMV-J1V组(合并第一空肠静脉切除,n=394)和PV/SMV-J2,3V组(合并第二或更远端空肠静脉分支切除,n=42)。
主要发现
- 术后并发症与死亡率在三组间无差异。
- PV/SMV重建相关术后并发症率:PV/SMV组11.9%,PV/SMV-J1V组8.6%,PV/SMV-J2,3V组7.1%,三组间无显著差异。
- PV/SMV组与PV/SMV-J1V组总生存无差异(中位生存29.2 vs 30.9个月,P=0.60)。
- PV/SMV-J2,3V组生存显著短于接受直接手术的PV/SMV组(P=0.05),但接受术前治疗患者的总生存无显著差异。
- 多因素生存分析显示,辅助治疗和R0切除是所有组中的独立预后因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to investigate the safety and survival benefits of portal vein and/or superior mesenteric vein (PV/SMV) resection with jejunal vein resection (JVR) for pancreatic ductal adenocarcinoma (PDAC). SUMMARY BACKGROUND DATA: Few studies have shown the surgical outcome and survival of pancreatic resection with JVR, and treatment strategies for patients with PDAC suspected of jejunal vein (JV) infiltration remain unclear. METHODS: In total, 1260 patients who underwent pancreatectomy with PV/ SMV resection between 2013 and 2016 at 50 facilities were included; treatment outcomes were compared between the PV/SMV group (PV/ SMV resection without JVR; n = 824), PV/SMV-J1 V group (PV/SMV resection with first jejunal vein resection; n = 394), and PV/SMV-J2,3 V group (PV/SMV resection with second jejunal vein or later branch resection; n = 42). RESULTS: Postoperative complications and mortality did not differ between the three groups. The postoperative complication rate associated with PV/ SMV reconstruction was 11.9% in PV/SMV group, 8.6% in PV/SMV-J1 V group, and 7.1% in PV/SMV-J2,3V group; there were no significant differences among the three groups. Overall survival did not differ between PV/SMV and PV/SMV-J1 V groups (median survival; 29.2 vs 30.9 months, P = 0.60). Although PV/SMV-J2,3 V group had significantly shorter survival than PV/SMV group who underwent upfront surgery ( P = 0.05), no significant differences in overall survival of patients who received preoperative therapy. Multivariate survival analysis revealed that adjuvant therapy and R0 resection were independent prognostic factors in all groups. CONCLUSION: PV/SMV resection with JVR can be safely performed and may provide satisfactory overall survival with the pre-and postoperative adjuvant therapy.
引用
- Nagakawa Y, Jang JY, Kawai M, et al. Surgical Outcomes of Pancreatectomy with Resection of the Portal Vein and/or Superior Mesenteric Vein and Jejunal Vein for Pancreatic Head Cancer: A Multicenter Study. Ann Surg. 2023. PMID: 34913900. doi:10.1097/SLA.0000000000005330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。